Eva Muñoz‐Couselo
Hebron University(PS)Hospital Universitario La Paz(ES)Vall d'Hebron Institut de Recerca(ES)Vall d'Hebron Hospital Universitari(ES)Vall d'Hebron Institute of OncologyVall d'Hebron Institute of Oncology(ES)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management
Most-Cited Works
- → The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies(2015)552 cited
- → Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial(2021)480 cited
- → Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study(2020)426 cited
- → Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.(2017)239 cited
- → <em>NRAS</em>-mutant melanoma: current challenges and future prospect(2017)159 cited
- → Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors